Reportable Segment and Major Concentrations Data (Tables)

12 Months Ended

Sep. 30, 2013

Segment Reporting [Abstract]

Consolidated Net Sales

Sales to individual customers constituting 10% or more of consolidated net sales are as follows:

Year Ended September 30,	2013				2012				2011
Customer A	$	35,082	(19	)%	$	32,771	(19	)%	$	29,632	(19	)%
Customer B	$	25,457	(13	)%	$	19,903	(12	)%	$	18,308	(11	)%

Significant Sales Information by Country for the Diagnostics and Life Science Reportable Segments

Significant sales information by country for the Diagnostics and Life Science segments is as follows. Sales are attributed to the geographic area based on the location to which the product is delivered.

Year Ended September 30,	2013		2012		2011
United States	$	114,935	$	99,998	$	89,078
Italy		7,427		7,473		8,544
United Kingdom		2,141		2,441		2,373
France		1,936		2,149		2,537
Holland		1,764		1,818		2,142
Belgium		1,285		1,271		1,289
Canada		1,248		941		892
Other countries		13,893		14,089		13,578
Total Diagnostics	$	144,629	$	130,180	$	120,433
Year Ended September 30,	2013		2012		2011
United States	$	17,527	$	17,805	$	15,711
Germany		6,465		4,872		4,922
United Kingdom		5,590		5,251		4,890
Australia		3,454		3,423		3,105
France		1,440		1,282		1,111
Other countries		9,581		9,899		8,664
Total Life Science	$	44,057	$	42,532	$	38,403

Segment Information

Segment information for the years ended September 30, 2013, 2012 and 2011 is as follows:

	Diagnostics		Life Science		Elim (1)			Total
Fiscal Year 2013—
Net sales –
Third-party	$	144,629	$	44,057	$	—		$	188,686
Inter-segment		533		1,223		(1,756	)		—
Operating income		46,735		10,627		(48	)		57,314
Depreciation and amortization		4,328		2,824		—			7,152
Capital expenditures		2,031		1,203		—			3,234
Goodwill		1,250		21,865		—			23,115
Other intangible assets		1,561		6,496		—			8,057
Total assets		112,054		110,111		(45,417	)		176,748
Fiscal Year 2012—
Net sales –
Third-party	$	130,180	$	42,532	$	—		$	172,712
Inter-segment		599		1,097		(1,696	)		—
Operating income (2)		40,648		8,473		175			49,296
Depreciation and amortization		3,732		2,865		—			6,597
Capital expenditures		2,341		1,189		—			3,530
Goodwill		1,250		21,896		—			23,146
Other intangible assets		2,239		8,025		—			10,264
Total assets		96,928		101,706		(37,253	)		161,381
Fiscal Year 2011—
Net sales –
Third-party	$	120,433	$	38,403	$	—		$	158,836
Inter-segment		152		756		(908	)		—
Operating income (3)		37,698		2,595		(260	)		40,033
Depreciation and amortization		2,970		2,903		—			5,873
Capital expenditures		5,041		4,098		—			9,139
Goodwill		1,381		21,743		—			23,124
Other intangible assets		1,604		9,343		—			10,947
Total assets		104,179		92,467		(41,153	)		155,493

(1) Eliminations consist of intersegment transactions.

(2) Life Science includes $1,013 related to consolidation of the Maine operations into the Tennessee facility.

(3) Diagnostics includes $1,240 related to sales and marketing leadership reorganization costs; and Life Science includes $1,057 related to consolidation of the Maine operations into the Tennessee facility.

Pre-tax Earnings Table

A reconciliation of segment operating income to consolidated earnings before income taxes for the years ended September 30, 2013, 2012 and 2011 is as follows:

Year Ended September 30,	2013		2012		2011
Segment operating income	$	57,314	$	49,296	$	40,033
Interest income		44		42		115
Other, net		4		378		352
Consolidated earnings before income taxes	$	57,362	$	49,716	$	40,500